RxDoctor Payments DataLook up a doctor →

Patrick Denard, MD

Orthopaedic Surgery · Medford, ORNPI 1578684627

Payments from drug & device makers

$14,075,067in general payments, 2019–2025

Across 2,176 payments — averaging $6468.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Arthrex$12.8M
  • Zurimed Technologies Inc.$1.2M
  • Encore Medical, LP$27K
  • Stryker$24K
  • Pacira Pharmaceuticals Incorporated$8K
  • Steelhead Surgical Inc$6K
  • plus $5K from 37 others
$124,677in research payments, 2019–2025

Across 34 payments — averaging $3666.96 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Arthrex$125K

What the payments were for

  • Royalty or licence$8,671,56275%
  • Consulting fees$1,041,3769%
  • Speaking & faculty fees$1,603,06514%
  • Travel & lodging$186,8952%
  • Food & beverage$24,6760%
  • Education$4,2700%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,075,067 in reported general payments places this provider in the 95th percentile of 228 orthopaedic surgery providers in Oregon.

See all orthopaedic surgery providers in Oregon

Medicare billing

Part B allowed, 2024
$429,801
Medicare patients
502
Services billed
1,837

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Methylprednisolone18$102
Oxycodone Hcl31$86
Ondansetron Hcl14$79
Meloxicam11$39
Gabapentin21$21

Paid to pharmacies, not to this prescriber.

Other orthopaedic surgery in Medford

See the full list for Oregon

Where these figures come from

Is this you, or does something look wrong? →